f Azole resistance in Aspergillus fumigatus is an emerging public health concern. Recently, a novel fungicide-driven mutation in the cyp51A gene and its promoter, TR 46 /Y121F/T289A, leading to high-level resistance to voriconazole has been identified in The Netherlands, Belgium, Germany, Denmark, Tanzania, and India in both clinical and environmental samples. Here we report the first description of A. fumigatus carrying this mutation in France, in a cystic fibrosis patient, underlining the need for extensive monitoring of Aspergillus resistance.
A zole-resistant Aspergillus fumigatus isolates have been increasingly reported in Europe since the later years of the first decade of the 2000s. This emerging public health concern occurs through two distinct routes of acquisition: in vivo selection of resistance as a consequence of long-term azole treatment and de novo acquisition of a resistant isolate directly from the environment, linked to the widespread use of azole fungicides in agriculture. Besides the TR 34 /L98H mutation in the cyp51A gene first described in The Netherlands, a novel fungicide-driven mutation, TR 46 /Y121F/T289A, has been recently identified. Until now, the TR 46 /Y121F/T289A mutation has been reported in both environmental and clinical samples in four countries across Europe (1-7), in Asia (8) , and, more recently, in Africa (9) , suggesting a large geographical spread. Here we provide the first description of A. fumigatus carrying a TR 46 /Y121F/T289A mutation in a cystic fibrosis patient in France.
A 23-year-old male cystic fibrosis patient with follow-up at the Pneumology Department at Rouen University Hospital, France, was seen in consultation in March 2014. This patient had high levels of total IgE and Aspergillus-specific IgE with positive Aspergillus-specific IgG antibodies, suggesting a diagnosis of allergic bronchopulmonary aspergillosis. He had a history of A. fumigatus airway colonization and exposure to mold-active azoles (itracona- Data represent results determined using CLSI breakpoints, except those indicated with an asterisk, which represent results determined using EUCAST breakpoints.
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zole and voriconazole) since 2002. At the time of the consultation, he was treated with voriconazole. Mycological cultures of the sputum collected during the consultation grew A. fumigatus (strain 1). Species identification was obtained by both macroscopic and microscopic characteristics on Sabouraud's agar medium together with sequencing of the beta-tubulin gene (10) . In accordance with a local research protocol aiming at the surveillance of azole resistance, this isolate was tested for antifungal susceptibility by the Etest method (bioMérieux, Marcy l'Etoile, France). Unexpectedly, this strain exhibited high-level resistance to voriconazole (MIC ϭ Ͼ32 g/ml) in comparison with itraconazole (MIC ϭ 8 g/ml) and posaconazole (MIC ϭ 1 g/ml). Antifungal susceptibility was confirmed by the EUCAST broth microdilution reference method (Table 1 ) (11, 12) . Nucleotide sequencing of the cyp51A gene and its promoter, using previously described primers (13, 14) Given these findings, we retrospectively analyzed all A. fumigatus strains that had been isolated from this patient since 2007 (n ϭ 13) for itraconazole and voriconazole susceptibility, cyp51A sequencing, and microsatellite genotyping. As shown in Table 1 , our patient had already been colonized by a TR 46 /Y121F/T289A isolate 1 year before, in February 2013 (strain 3). All remaining isolates collected before February 2013 were azole susceptible, either being wild type for the cyp51A gene or carrying mutations previously found in both azole-resistant and azole-susceptible isolates (15) . As only a single colony was subjected to in vitro susceptibility testing, other azole-resistant isolates could have been missed. Microsatellite genotyping was performed using a panel of nine short tandem repeats as described previously (16) . As illustrated in Table 1, both TR 46 /Y121F/T289A isolates from our patient had the same genotype as a strain previously isolated in Germany (7) (Table 1). To gain further insights into the route of acquisition of this azole-resistant isolate in our patient, we conducted an environmental study by performing soil samplings next to the patient's home as described previously (17), as well as surface samplings (contact agar plates) in his office. Neither A. fumigatus carrying TR 46 /Y121F/T289A nor A. fumigatus carrying TR 34 /L98H was identified.
Aspergillus fumigatus isolates carrying the TR 46 /Y121F/T289A mutation were first described in December 2009 in The Netherlands (2). Since then, such isolates have been evidenced in three other European countries, namely, Belgium (1, 5), Germany (3, 7), and Denmark (4), and recently in India (8) and Tanzania (9) ( Table 2 and Fig. 1 ). Taken together, these findings suggest, as discussed previously for TR 34 /L98H isolates, a large geographical spread of this resistance mechanism. Several lines of evidence indicate that, as in the case of TR 34 /L98H, TR 46 /Y121F/T289A has emerged through a fungicide-driven route (18) , such isolates being found in both azole-naive patients (1, 2, 6, 7) and azole-exposed patients (2, 3, 5, 7) as well as in samples from the environment (2, 8, 9) . Here we report the first description of A. fumigatus carrying the TR 46 /Y121F/ T289A mutation isolated from a French patient.
Interestingly, our patient organized trips to The Netherlands as a tour operator. For these working purposes, he traveled to Amsterdam in November 2012, 3 months before the first isolation of the TR 46 /Y121F/T289A strain from his sputum (February 2013). Moreover, he regularly received advertising postal packages from Dutch flower producers which were opened in his office. Three hypotheses can explain the route of acquisition of this TR 46 /Y121F/T289A strain in our patient. (i) The first hypothesis is that he inhaled spores carrying TR 46 / Y121F/T289A during his trip to The Netherlands (2). (ii) The second hypothesis is that colonization occurred after he inhaled spores carrying TR 46 /Y121F/T289A from his environment in France. Our environmental study conducted next to the patient's home, less than 100 km from Belgium (where TR 46 /Y121F/T289A strains have been recently identified [1] ), failed to detect TR 46 /Y121F/T289A environmental isolates. Nevertheless, environmental isolates carrying this mutation have been recently identified by our team in the same region in France, supporting this hypothesis (unpublished data). (iii) The last hypothesis is that colonization occurred after he inhaled A. fumigatus spores carrying TR 46 /Y121F/T289A that had escaped while he was opening the packages received from The Netherlands. Though the French strains are genetically indistinguishable from the German isolates and genetically different from the Dutch isolates (Fig. 2) , the route of acquisition in our patient is unclear, as the spores probably followed an airborne migration pattern as hypothesized previously for TR 34 /L98H (19, 20) .
The present report provides evidence that A. fumigatus voriconazole-resistant isolates carrying the TR 46 /Y121F/T289A mutation can be now isolated from clinical samples in France. As observed with TR 34 /L98H, a geographical spread of this resistance mechanism is ongoing across Europe and possibly worldwide. These findings, together with the high-level voriconazole resistance of the TR 46 /Y121F/T289A strains both in vitro and in vivo (1, 2, (4) (5) (6) , underline the need for intensive investigations to determine the prevalence of the mutation in both clinical and environmental samples. In line with this, as recommended by a European Centre for Disease Prevention and Control (ECDC) technical report (18) , antifungal susceptibility testing of triazoles should be performed on all clinical A. fumigatus isolates before starting antifungal therapy.
